Published: Thu, February 15, 2018
Business | By Tara Barton

Ligand Pharmaceuticals Inc. (LGND) CEO Sells 22500 Shares of Stock

Following the completion of the transaction, the director now owns 26,985 shares of the company's stock, valued at $3,703,691.25. Essex Ppty Tr Inc now has $15.35B valuation. 398,003 shares of the company traded hands, compared to its average volume of 324,858. InterXion Holding N.V. (NYSE:INXN) has risen 30.50% since February 13, 2017 and is uptrending. It has underperformed by 16.70% the S&P500.

Falcon Point Capital Llc decreased Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 10.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. It also increased its holding in Talend Sa Sponsored Adr by 347,245 shares in the quarter, for a total of 548,480 shares, and has risen its stake in Red Hat Inc. (LGND)'s stock rose 7.66%. Capstone Asset Management Co. now owns 2,813 shares of the biotechnology company's stock worth $341,000 after purchasing an additional 100 shares during the last quarter. Ligand Pharmaceuticals has a 12-month low of $87.50 and a 12-month high of $144.86. The stock increased 3.09% or $4.71 during the last trading session, reaching $157.25. About 102,354 shares traded. It has underperformed by 19.57% the S&P500.

Among 8 analysts covering Trimas (NASDAQ:TRS), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 92% are positive. The stock of TriMas Corporation (NASDAQ:TRS) has "Hold" rating given on Thursday, June 15 by Jefferies. The stock of Celgene Corporation (NASDAQ:CELG) has "Hold" rating given on Wednesday, November 9 by Standpoint Research. As per Friday, September 18, the company rating was initiated by DA Davidson. The rating was maintained by Guggenheim with "Buy" on Thursday, January 25. The firm has "Hold" rating given on Monday, July 17 by Deutsche Bank. The stock has "Hold" rating by Seaport Global on Friday, September 15. The brokerage now has a buy rating on the biotechnology company's stock. The firm has "Sell" rating by Zelman given on Wednesday, January 27. It is down 0.00% since February 14, 2017 and is. Profund Advisors Lc owns 10,966 shares. EUDY JOHN D sold 166 shares worth $42,815. Aryeh Jason sold $255,980 worth of stock. They expect $0.92 EPS, up 713.33% or $1.07 from last year's $-0.15 per share. The number of shares now owned by investors are 21.1 mln. 25 funds opened positions while 42 raised stakes. Hightower Advsrs Ltd has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). 15,848 were reported by Hartford Invest Management. Rhumbline Advisers holds 0.01% or 43,518 shares.

Birchview Capital Lp holds 57.32% of its portfolio in Celgene Corporation for 761,051 shares. (NYSE:ESS) for 24,399 shares. Lombard Odier Asset Management (Switzerland) holds 9,376 shares. Automobile Association has 33,200 shares for 0.01% of their portfolio. Transamerica Advsr Inc reported 4 shares. "(LGND)" was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online.

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive.

LGND has been the topic of several analyst reports. Below is a list of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) latest ratings and price target changes. The firm has "Buy" rating by Roth Capital given on Monday, September 21. Insiders own 8.30% of the company's stock. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has declined 2.87% since February 10, 2017 and is downtrending. H.C. Wainwright has "Buy" rating and $157.0 target. As per Wednesday, September 30, the company rating was maintained by TH Capital. TH Capital maintained it with "Buy" rating and $146 target in Friday, December 18 report.

Chad Sayers Replaces Jackson Bird For South Africa Tour
Sayers , 30, has yet to win a Test cap but will join the Australian squad for their four-Test series starting on March 1. South Australia's Chadd Sayers has been named as the replacement for Bird for the 4-match Test series.

In an overview of the current analyst recommendations, Buy count is 0 and Overweight is 0 while the number of analysts recommending Sell and Underweight are 0 and 0, respectively. Zacks Investment Research upgraded Ligand Pharmaceuticals from a "hold" rating to a "strong-buy" rating and set a $165.00 target price for the company in a research report on Thursday, October 12th. Canaccord Genuity maintained the shares of INXN in report on Thursday, November 5 with "Buy" rating. Roth Capital set a $158.00 price target on shares of Ligand Pharmaceuticals and gave the company a "buy" rating in a report on Monday, November 13th. Paratek Pharma (NASDAQ:PRTK) was raised too.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings results on Monday, August 7th. They expect $0.32 EPS, up 6.67% or $0.02 from last year's $0.3 per share. LGND's profit will be $19.41 million for 41.45 P/E if the $0.92 EPS becomes a reality. Conestoga Capital Advisors LLC raised its holdings in Ligand Pharmaceuticals by 13.1% in the fourth quarter.

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.45, from 1.24 in 2017Q2. It improved, as 19 investors sold LGND shares while 68 reduced holdings. 80 funds opened positions while 232 raised stakes. Clearbridge Invs Ltd Com stated it has 353 shares. Intrust Bancshares Na stated it has 2,556 shares. Metropolitan Life Insur owns 31,468 shares. Ngam Limited Partnership holds 106,384 shares or 0.03% of its portfolio. Riverhead Cap Mgmt Ltd Company has 0.01% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Thompson Davis & accumulated 0.04% or 155 shares. Granite Investment Prtnrs Limited Liability Co owns 117,396 shares or 0.99% of their USA portfolio. Ligand Pharmaceuticals earned a coverage optimism score of 0.14 on Accern's scale. M&T Natl Bank has 1,584 shares for 0% of their portfolio. Elk Creek Prns Ltd Com accumulated 1.12% or 130,905 shares. Century Cos Incorporated reported 14,488 shares. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.97 and a quick ratio of 0.95. The Company is involved in the development and licensing of biopharmaceutical assets.

Since August 23, 2017, it had 0 insider purchases, and 6 selling transactions for $9.43 million activity. Healthinvest Partners Ab sold 8,300 shares as the company's stock rose 7.66% with the market. Also, Director Stephen L. Sabba sold 925 shares of the stock in a transaction that occurred on Wednesday, December 20th.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Like this: